poh shareholder meeting, page-15

I think it is inportant to note that decisions on moving forward are made in conjunction with the clinical, scientific and commercial divisions of the team, with advise from neura.
There was an interesting discussion with macca regarding the balance between the scientist wanting perfection where as the business team wants a commercial viable product as soon as possible.
There is also a theory that whether a phase II will be sufficient to secure a sound commercial deal - as a single product or infact as a whole pain portfolio.